Imatinib IP

May 03, 2023

Imatinib IP
IMATIFLOW is a type of medication that is used to treat certain types of cancer, such as chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GISTs), and some types of acute lymphoblastic leukemia (ALL). It is a protein tyrosine kinase inhibitor that works by blocking the action of abnormal proteins that signal cancer cells to grow and divide.
The "IP" in Imatinib IP stands for "Indian Pharmacopoeia," indicating that the medication meets the quality standards established by the Indian Pharmacopoeia Commission.
IMATIFLOW is usually taken orally, in the form of a tablet, and it is important to take it as directed by a healthcare provider. The dosage and duration of treatment may vary depending on the type and stage of cancer being treated, as well as other factors such as age and overall health. It is important to talk to a healthcare provider about any questions or concerns regarding IMATIFLOW or any other medication.
For further information please contact:
info@sterispharma.com

SHARE WITH